James Miller
Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 44 | 2020 | 2323 | 2.750 |
Why?
| Smoking | 20 | 2019 | 1463 | 1.280 |
Why?
| Bronchi | 13 | 2018 | 240 | 1.230 |
Why?
| Carcinoma in Situ | 5 | 2019 | 45 | 1.120 |
Why?
| Carcinoma, Squamous Cell | 10 | 2018 | 620 | 0.780 |
Why?
| Carcinogens | 4 | 2012 | 110 | 0.770 |
Why?
| Chemoprevention | 3 | 2019 | 89 | 0.730 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 81 | 0.730 |
Why?
| Lung | 16 | 2020 | 3741 | 0.630 |
Why?
| Carcinoma, Small Cell | 7 | 2008 | 168 | 0.500 |
Why?
| Bronchoscopy | 9 | 2019 | 208 | 0.500 |
Why?
| Urethane | 3 | 2012 | 41 | 0.490 |
Why?
| Bronchopulmonary Dysplasia | 2 | 2019 | 375 | 0.480 |
Why?
| Pulmonary Alveoli | 4 | 2012 | 366 | 0.470 |
Why?
| Sputum | 8 | 2019 | 304 | 0.470 |
Why?
| Iloprost | 2 | 2012 | 45 | 0.460 |
Why?
| Hyperplasia | 7 | 2011 | 170 | 0.460 |
Why?
| Precancerous Conditions | 7 | 2020 | 161 | 0.450 |
Why?
| Neprilysin | 3 | 1998 | 47 | 0.430 |
Why?
| Biomarkers, Tumor | 7 | 2015 | 1182 | 0.400 |
Why?
| Quinazolines | 2 | 2012 | 242 | 0.400 |
Why?
| Piperidines | 2 | 2012 | 190 | 0.390 |
Why?
| Biopsy | 11 | 2019 | 1085 | 0.390 |
Why?
| Antineoplastic Agents | 4 | 2013 | 2058 | 0.390 |
Why?
| DNA Copy Number Variations | 1 | 2011 | 169 | 0.350 |
Why?
| Bombesin | 5 | 1998 | 12 | 0.350 |
Why?
| Genetic Markers | 1 | 2011 | 339 | 0.350 |
Why?
| Amidohydrolases | 3 | 1998 | 30 | 0.340 |
Why?
| Neurosecretory Systems | 4 | 2004 | 30 | 0.330 |
Why?
| Carcinoma, Non-Small-Cell Lung | 7 | 2013 | 1044 | 0.320 |
Why?
| Ki-67 Antigen | 3 | 2015 | 106 | 0.320 |
Why?
| Tocopherols | 1 | 2009 | 22 | 0.320 |
Why?
| Isotretinoin | 1 | 2009 | 23 | 0.320 |
Why?
| Vasodilator Agents | 1 | 2011 | 321 | 0.320 |
Why?
| ErbB Receptors | 1 | 2012 | 601 | 0.310 |
Why?
| Mass Screening | 3 | 2008 | 1152 | 0.300 |
Why?
| Membrane Proteins | 2 | 2008 | 1108 | 0.300 |
Why?
| Pulmonary Disease, Chronic Obstructive | 4 | 2018 | 950 | 0.290 |
Why?
| Neovascularization, Pathologic | 6 | 2015 | 291 | 0.290 |
Why?
| Respiratory Mucosa | 2 | 2008 | 305 | 0.260 |
Why?
| Adenocarcinoma | 6 | 2012 | 888 | 0.250 |
Why?
| Hypoxia | 1 | 2012 | 1031 | 0.240 |
Why?
| Chromosomes, Human, Pair 3 | 4 | 2000 | 48 | 0.230 |
Why?
| Carcinoma, Bronchogenic | 2 | 2002 | 19 | 0.220 |
Why?
| Chromosome Aberrations | 4 | 2013 | 147 | 0.210 |
Why?
| Middle Aged | 28 | 2019 | 30893 | 0.210 |
Why?
| Aged | 25 | 2019 | 21971 | 0.210 |
Why?
| Tomography, Spiral Computed | 1 | 2002 | 27 | 0.200 |
Why?
| Humans | 53 | 2020 | 128524 | 0.190 |
Why?
| Female | 33 | 2019 | 68127 | 0.190 |
Why?
| Sensitivity and Specificity | 10 | 2010 | 1820 | 0.190 |
Why?
| Smokers | 2 | 2019 | 137 | 0.190 |
Why?
| Placebos | 2 | 2019 | 201 | 0.180 |
Why?
| Double-Blind Method | 2 | 2019 | 1860 | 0.180 |
Why?
| Lung Diseases | 5 | 2015 | 722 | 0.180 |
Why?
| Small Cell Lung Carcinoma | 2 | 2012 | 88 | 0.180 |
Why?
| Tomography, X-Ray Computed | 2 | 2020 | 2521 | 0.170 |
Why?
| Male | 30 | 2019 | 62883 | 0.170 |
Why?
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 91 | 0.160 |
Why?
| Tumor Cells, Cultured | 6 | 1998 | 927 | 0.160 |
Why?
| Neuropeptides | 4 | 1998 | 72 | 0.160 |
Why?
| Remission Induction | 1 | 2019 | 269 | 0.150 |
Why?
| Peptides | 3 | 1996 | 909 | 0.150 |
Why?
| In Situ Hybridization, Fluorescence | 6 | 2010 | 313 | 0.150 |
Why?
| Blotting, Western | 4 | 2012 | 1168 | 0.150 |
Why?
| Genes, p53 | 1 | 1997 | 70 | 0.140 |
Why?
| Lung Diseases, Obstructive | 1 | 1997 | 44 | 0.140 |
Why?
| Antibodies, Monoclonal | 3 | 2010 | 1355 | 0.140 |
Why?
| Immunohistochemistry | 8 | 2015 | 1669 | 0.130 |
Why?
| Point Mutation | 1 | 1997 | 224 | 0.130 |
Why?
| Proteomics | 2 | 2015 | 1004 | 0.130 |
Why?
| Radiation Injuries, Experimental | 1 | 1996 | 22 | 0.130 |
Why?
| Bradykinin | 1 | 1996 | 45 | 0.130 |
Why?
| Endopeptidases | 1 | 1996 | 83 | 0.130 |
Why?
| Chromosomal Instability | 2 | 2013 | 18 | 0.130 |
Why?
| Mice | 10 | 2012 | 16579 | 0.120 |
Why?
| Animals | 13 | 2013 | 34501 | 0.120 |
Why?
| Smoking Cessation | 1 | 2019 | 408 | 0.120 |
Why?
| Hyperoxia | 1 | 1996 | 87 | 0.120 |
Why?
| Multiple Pulmonary Nodules | 1 | 2015 | 19 | 0.120 |
Why?
| Gene Expression | 3 | 1998 | 1462 | 0.110 |
Why?
| Methylcholanthrene | 2 | 2012 | 21 | 0.110 |
Why?
| Risk Factors | 5 | 2019 | 9727 | 0.110 |
Why?
| Mice, Transgenic | 5 | 2009 | 2069 | 0.110 |
Why?
| Antigens | 1 | 1996 | 352 | 0.110 |
Why?
| Butylated Hydroxytoluene | 2 | 2012 | 38 | 0.110 |
Why?
| Aged, 80 and over | 8 | 2015 | 7040 | 0.110 |
Why?
| Microarray Analysis | 1 | 2013 | 121 | 0.110 |
Why?
| Algorithms | 3 | 2020 | 1616 | 0.110 |
Why?
| Stem Cells | 1 | 2018 | 578 | 0.110 |
Why?
| Mutation | 4 | 2000 | 3692 | 0.110 |
Why?
| Epithelium | 4 | 2018 | 306 | 0.110 |
Why?
| Intramolecular Oxidoreductases | 2 | 2004 | 62 | 0.100 |
Why?
| Risk | 5 | 2012 | 852 | 0.100 |
Why?
| Carcinoma, Large Cell | 1 | 2012 | 15 | 0.100 |
Why?
| Cytochrome P-450 Enzyme System | 2 | 2004 | 127 | 0.100 |
Why?
| Biological Products | 1 | 1996 | 200 | 0.100 |
Why?
| Epithelial Cells | 3 | 2007 | 1036 | 0.100 |
Why?
| Receptors, Bombesin | 1 | 2012 | 2 | 0.100 |
Why?
| Bronchoalveolar Lavage Fluid | 3 | 2002 | 626 | 0.100 |
Why?
| Volatile Organic Compounds | 1 | 2012 | 54 | 0.100 |
Why?
| Case-Control Studies | 8 | 2012 | 3326 | 0.100 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 206 | 0.100 |
Why?
| Cell Division | 4 | 2000 | 779 | 0.100 |
Why?
| Sleep Apnea Syndromes | 1 | 2012 | 78 | 0.090 |
Why?
| Dose-Response Relationship, Drug | 2 | 2010 | 1943 | 0.090 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 129 | 0.090 |
Why?
| Chromosomes, Human, Pair 15 | 1 | 2011 | 56 | 0.090 |
Why?
| Veterans | 1 | 2002 | 1414 | 0.090 |
Why?
| Eosinophilic Granuloma | 1 | 1990 | 3 | 0.090 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2012 | 194 | 0.090 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 231 | 0.090 |
Why?
| Antioxidants | 2 | 2012 | 543 | 0.090 |
Why?
| Proteins | 1 | 1996 | 936 | 0.080 |
Why?
| Cell Line | 5 | 2013 | 2731 | 0.080 |
Why?
| Plants, Toxic | 1 | 1989 | 22 | 0.080 |
Why?
| Somatomedins | 1 | 2009 | 28 | 0.080 |
Why?
| Calcium | 1 | 1996 | 1178 | 0.080 |
Why?
| Predictive Value of Tests | 4 | 2009 | 1936 | 0.080 |
Why?
| Genome-Wide Association Study | 2 | 2013 | 1337 | 0.080 |
Why?
| Disease Progression | 5 | 2018 | 2603 | 0.080 |
Why?
| Cell Proliferation | 2 | 2018 | 2335 | 0.080 |
Why?
| Adult | 16 | 2018 | 35315 | 0.080 |
Why?
| Intracellular Signaling Peptides and Proteins | 2 | 2011 | 425 | 0.080 |
Why?
| Bronchial Neoplasms | 1 | 2009 | 14 | 0.080 |
Why?
| Chromosome Deletion | 1 | 1989 | 102 | 0.080 |
Why?
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 35 | 0.080 |
Why?
| Airway Obstruction | 3 | 2009 | 149 | 0.080 |
Why?
| GPI-Linked Proteins | 1 | 2008 | 67 | 0.070 |
Why?
| Respiratory System | 1 | 1989 | 153 | 0.070 |
Why?
| Neoplasm Invasiveness | 4 | 2015 | 480 | 0.070 |
Why?
| Fluorescence | 3 | 2009 | 158 | 0.070 |
Why?
| Alkaline Phosphatase | 1 | 2008 | 142 | 0.070 |
Why?
| Polymorphism, Genetic | 1 | 2011 | 639 | 0.070 |
Why?
| Spectral Karyotyping | 1 | 2007 | 5 | 0.070 |
Why?
| Isoenzymes | 1 | 2008 | 304 | 0.070 |
Why?
| Inflammation | 1 | 2018 | 2664 | 0.070 |
Why?
| Molecular Targeted Therapy | 1 | 2010 | 387 | 0.070 |
Why?
| Cell Transformation, Neoplastic | 1 | 2009 | 325 | 0.070 |
Why?
| Fibroblasts | 3 | 1998 | 939 | 0.070 |
Why?
| Molecular Sequence Data | 5 | 1998 | 2818 | 0.070 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2008 | 259 | 0.070 |
Why?
| Pulmonary Surfactants | 2 | 1999 | 106 | 0.070 |
Why?
| Exons | 2 | 1998 | 337 | 0.070 |
Why?
| Early Detection of Cancer | 1 | 2010 | 368 | 0.070 |
Why?
| Follow-Up Studies | 2 | 2015 | 4898 | 0.060 |
Why?
| MicroRNAs | 1 | 2012 | 671 | 0.060 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2013 | 2065 | 0.060 |
Why?
| ROC Curve | 3 | 2015 | 501 | 0.060 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2005 | 814 | 0.060 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 391 | 0.060 |
Why?
| Recombinant Proteins | 3 | 1998 | 1284 | 0.060 |
Why?
| RNA, Messenger | 3 | 1998 | 2674 | 0.060 |
Why?
| Biomarkers | 3 | 2010 | 3881 | 0.060 |
Why?
| Polymerase Chain Reaction | 3 | 1998 | 1019 | 0.060 |
Why?
| Growth Hormone-Releasing Hormone | 1 | 2004 | 24 | 0.060 |
Why?
| Acromegaly | 1 | 2004 | 12 | 0.060 |
Why?
| Protein Kinase Inhibitors | 1 | 2010 | 872 | 0.060 |
Why?
| Cytokines | 1 | 2012 | 1985 | 0.060 |
Why?
| Rats | 4 | 2004 | 5168 | 0.050 |
Why?
| Adrenocorticotropic Hormone | 1 | 2004 | 132 | 0.050 |
Why?
| Neoplasm Recurrence, Local | 1 | 2009 | 957 | 0.050 |
Why?
| Smoke | 1 | 2004 | 132 | 0.050 |
Why?
| Base Sequence | 3 | 1998 | 2134 | 0.050 |
Why?
| Solitary Pulmonary Nodule | 1 | 2002 | 20 | 0.050 |
Why?
| Cross-Sectional Studies | 2 | 2018 | 5040 | 0.050 |
Why?
| Metaplasia | 2 | 2018 | 54 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2005 | 501 | 0.050 |
Why?
| Sex Factors | 1 | 2007 | 1949 | 0.050 |
Why?
| Radiation Dosage | 1 | 2002 | 152 | 0.050 |
Why?
| Pulmonary Fibrosis | 2 | 1998 | 374 | 0.050 |
Why?
| Hospitals, Veterans | 1 | 2002 | 257 | 0.050 |
Why?
| Reproducibility of Results | 1 | 2008 | 3023 | 0.040 |
Why?
| Gene Expression Regulation | 1 | 1989 | 2506 | 0.040 |
Why?
| Cohort Studies | 4 | 2015 | 5369 | 0.040 |
Why?
| Amino Acid Sequence | 3 | 1994 | 2041 | 0.040 |
Why?
| Gastrin-Releasing Peptide | 2 | 1996 | 7 | 0.040 |
Why?
| Feasibility Studies | 1 | 2002 | 860 | 0.040 |
Why?
| Light | 1 | 2001 | 355 | 0.040 |
Why?
| Autocrine Communication | 1 | 1998 | 43 | 0.040 |
Why?
| gamma Catenin | 1 | 2018 | 13 | 0.040 |
Why?
| Signal Transduction | 3 | 1998 | 4829 | 0.040 |
Why?
| Desmoglein 3 | 1 | 2018 | 16 | 0.040 |
Why?
| Loss of Heterozygosity | 2 | 2013 | 46 | 0.040 |
Why?
| DNA Primers | 2 | 1998 | 510 | 0.040 |
Why?
| Up-Regulation | 2 | 2005 | 826 | 0.040 |
Why?
| Paracrine Communication | 1 | 1998 | 60 | 0.040 |
Why?
| Bronchial Diseases | 1 | 2018 | 38 | 0.040 |
Why?
| Neoplasm Transplantation | 1 | 1998 | 258 | 0.040 |
Why?
| Time | 1 | 2018 | 75 | 0.040 |
Why?
| Gene Expression Profiling | 1 | 2005 | 1687 | 0.040 |
Why?
| Vascular Cell Adhesion Molecule-1 | 1 | 1998 | 37 | 0.040 |
Why?
| Telangiectasia, Hereditary Hemorrhagic | 1 | 1998 | 12 | 0.040 |
Why?
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 28 | 0.040 |
Why?
| Cell Cycle Checkpoints | 1 | 2018 | 95 | 0.040 |
Why?
| Genes, Tumor Suppressor | 1 | 1998 | 86 | 0.040 |
Why?
| Alveolitis, Extrinsic Allergic | 1 | 1998 | 92 | 0.040 |
Why?
| Likelihood Functions | 1 | 1998 | 136 | 0.040 |
Why?
| Polymorphism, Restriction Fragment Length | 1 | 1997 | 69 | 0.040 |
Why?
| DNA, Complementary | 1 | 1998 | 267 | 0.040 |
Why?
| Neoplasm Staging | 2 | 2012 | 1288 | 0.040 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 1998 | 283 | 0.040 |
Why?
| Codon | 1 | 1997 | 86 | 0.040 |
Why?
| United States | 2 | 2011 | 13876 | 0.030 |
Why?
| Introns | 1 | 1998 | 245 | 0.030 |
Why?
| Mice, Nude | 1 | 1998 | 682 | 0.030 |
Why?
| Treatment Outcome | 1 | 2011 | 10163 | 0.030 |
Why?
| Membrane Glycoproteins | 1 | 1999 | 466 | 0.030 |
Why?
| Immunoassay | 2 | 1998 | 103 | 0.030 |
Why?
| Incidence | 3 | 2010 | 2619 | 0.030 |
Why?
| Enzyme Activation | 1 | 1998 | 799 | 0.030 |
Why?
| RNA, Neoplasm | 1 | 1996 | 87 | 0.030 |
Why?
| Glycopeptides | 1 | 1996 | 44 | 0.030 |
Why?
| Mesothelioma | 1 | 1996 | 38 | 0.030 |
Why?
| Image Processing, Computer-Assisted | 1 | 2020 | 732 | 0.030 |
Why?
| Antigens, CD | 2 | 1998 | 479 | 0.030 |
Why?
| Machine Learning | 1 | 2020 | 432 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 1998 | 773 | 0.030 |
Why?
| Proto-Oncogene Proteins | 1 | 2018 | 634 | 0.030 |
Why?
| Databases, Factual | 1 | 2020 | 1268 | 0.030 |
Why?
| Cell Cycle Proteins | 1 | 2018 | 580 | 0.030 |
Why?
| Receptors, Peptide | 1 | 1994 | 17 | 0.030 |
Why?
| Myelin Sheath | 1 | 1996 | 159 | 0.030 |
Why?
| Rh-Hr Blood-Group System | 1 | 1994 | 11 | 0.030 |
Why?
| Erythrocyte Membrane | 1 | 1994 | 49 | 0.030 |
Why?
| Blotting, Southern | 1 | 1993 | 68 | 0.030 |
Why?
| Prospective Studies | 3 | 2012 | 7043 | 0.030 |
Why?
| Blotting, Northern | 1 | 1993 | 199 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 1996 | 608 | 0.030 |
Why?
| Endoscopy | 1 | 2015 | 267 | 0.030 |
Why?
| Cells, Cultured | 2 | 2007 | 4008 | 0.030 |
Why?
| DNA, Neoplasm | 1 | 1993 | 159 | 0.030 |
Why?
| Solid Phase Microextraction | 1 | 2012 | 6 | 0.030 |
Why?
| Liver Neoplasms | 1 | 1998 | 640 | 0.030 |
Why?
| Fluorescent Antibody Technique | 1 | 1993 | 374 | 0.030 |
Why?
| Dinoprostone | 2 | 2004 | 187 | 0.030 |
Why?
| Colorado | 1 | 2002 | 4392 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 1996 | 811 | 0.020 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2012 | 126 | 0.020 |
Why?
| Cloning, Molecular | 1 | 1993 | 522 | 0.020 |
Why?
| Breath Tests | 1 | 2012 | 89 | 0.020 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1333 | 0.020 |
Why?
| Iceland | 1 | 2011 | 10 | 0.020 |
Why?
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2011 | 12 | 0.020 |
Why?
| Spain | 1 | 2011 | 36 | 0.020 |
Why?
| Respiratory Tract Diseases | 1 | 1992 | 150 | 0.020 |
Why?
| Netherlands | 1 | 2011 | 77 | 0.020 |
Why?
| Cattle | 1 | 1993 | 962 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 1996 | 2245 | 0.020 |
Why?
| Administration, Oral | 1 | 2012 | 757 | 0.020 |
Why?
| Meta-Analysis as Topic | 1 | 2011 | 167 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2018 | 2736 | 0.020 |
Why?
| Carrier Proteins | 1 | 1994 | 731 | 0.020 |
Why?
| Prognosis | 2 | 2012 | 3780 | 0.020 |
Why?
| Flow Cytometry | 1 | 1993 | 1141 | 0.020 |
Why?
| Receptor, IGF Type 1 | 1 | 2009 | 65 | 0.020 |
Why?
| Area Under Curve | 1 | 2010 | 281 | 0.020 |
Why?
| International Agencies | 1 | 2009 | 29 | 0.020 |
Why?
| Cystic Fibrosis | 1 | 1998 | 1057 | 0.020 |
Why?
| Erythrocytes | 1 | 1994 | 670 | 0.020 |
Why?
| Chromatography, High Pressure Liquid | 1 | 1989 | 475 | 0.020 |
Why?
| Mass Spectrometry | 1 | 2010 | 660 | 0.020 |
Why?
| Pilot Projects | 1 | 2012 | 1558 | 0.020 |
Why?
| Genome, Human | 1 | 2009 | 392 | 0.020 |
Why?
| Models, Statistical | 1 | 2010 | 625 | 0.020 |
Why?
| Amino Acids | 1 | 1989 | 474 | 0.020 |
Why?
| Disease Models, Animal | 1 | 1996 | 3943 | 0.020 |
Why?
| Genotype | 1 | 2011 | 1831 | 0.020 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 89 | 0.010 |
Why?
| Genomics | 1 | 2009 | 716 | 0.010 |
Why?
| Epoprostenol | 1 | 2004 | 134 | 0.010 |
Why?
| Bronchiolitis | 1 | 2004 | 89 | 0.010 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 937 | 0.010 |
Why?
| Autoantibodies | 1 | 2010 | 1463 | 0.010 |
Why?
| Fruit | 1 | 2003 | 131 | 0.010 |
Why?
| Vegetables | 1 | 2003 | 147 | 0.010 |
Why?
| Pituitary Neoplasms | 1 | 2004 | 184 | 0.010 |
Why?
| Genetic Predisposition to Disease | 1 | 2011 | 2266 | 0.010 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 756 | 0.010 |
Why?
| Respiratory Function Tests | 1 | 2004 | 582 | 0.010 |
Why?
| Adenoma | 1 | 2004 | 214 | 0.010 |
Why?
| Regression Analysis | 1 | 2003 | 983 | 0.010 |
Why?
| Single-Blind Method | 1 | 2001 | 269 | 0.010 |
Why?
| Weight Gain | 1 | 2004 | 505 | 0.010 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 56 | 0.010 |
Why?
| Carcinoma | 1 | 2001 | 214 | 0.010 |
Why?
| RNA | 1 | 2005 | 881 | 0.010 |
Why?
| Bronchoscopes | 1 | 1998 | 2 | 0.010 |
Why?
| Endoglin | 1 | 1998 | 19 | 0.010 |
Why?
| Random Allocation | 1 | 1998 | 346 | 0.010 |
Why?
| Retrospective Studies | 1 | 2015 | 14460 | 0.010 |
Why?
| Genetic Linkage | 1 | 1998 | 299 | 0.010 |
Why?
| Reference Values | 1 | 1998 | 780 | 0.010 |
Why?
| Comorbidity | 1 | 2001 | 1540 | 0.010 |
Why?
| Longitudinal Studies | 1 | 2003 | 2697 | 0.010 |
Why?
| Linear Models | 1 | 1998 | 816 | 0.010 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2000 | 507 | 0.010 |
Why?
| Diet | 1 | 2003 | 1200 | 0.010 |
Why?
| Receptors, Cell Surface | 1 | 1998 | 371 | 0.010 |
Why?
| Analysis of Variance | 1 | 1998 | 1271 | 0.010 |
Why?
| Alleles | 1 | 1998 | 845 | 0.010 |
Why?
| Young Adult | 1 | 2011 | 12320 | 0.010 |
Why?
| Infant, Premature | 1 | 1998 | 536 | 0.010 |
Why?
| Risk Assessment | 1 | 2004 | 3256 | 0.010 |
Why?
| Chromatography, Affinity | 1 | 1994 | 83 | 0.010 |
Why?
| CD47 Antigen | 1 | 1994 | 27 | 0.010 |
Why?
| Genes | 1 | 1994 | 226 | 0.010 |
Why?
| Moths | 1 | 1994 | 38 | 0.010 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 323 | 0.010 |
Why?
| Endothelium, Vascular | 1 | 2000 | 871 | 0.010 |
Why?
| Cytoplasm | 1 | 1994 | 258 | 0.010 |
Why?
| Carcinoid Tumor | 1 | 1992 | 24 | 0.010 |
Why?
| Chromosome Mapping | 1 | 1994 | 505 | 0.010 |
Why?
| Lymphocytes | 1 | 1994 | 366 | 0.010 |
Why?
| Adolescent | 1 | 2011 | 20213 | 0.010 |
Why?
| Transfection | 1 | 1994 | 895 | 0.010 |
Why?
| Mice, Inbred BALB C | 1 | 1994 | 1229 | 0.010 |
Why?
| Dyspnea | 1 | 1992 | 234 | 0.010 |
Why?
| Binding Sites | 1 | 1994 | 1239 | 0.010 |
Why?
| Fibrosis | 1 | 1992 | 522 | 0.010 |
Why?
| Phenotype | 1 | 1998 | 3050 | 0.000 |
Why?
| Aging | 1 | 1998 | 1770 | 0.000 |
Why?
| Infant, Newborn | 1 | 1998 | 5687 | 0.000 |
Why?
| Infant | 1 | 1998 | 8913 | 0.000 |
Why?
| Child, Preschool | 1 | 1998 | 10373 | 0.000 |
Why?
| Child | 1 | 1998 | 20721 | 0.000 |
Why?
|
|
Miller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|